Palvella Therapeutics
PVLA
115 hedge funds and large institutions have $179M invested in Palvella Therapeutics in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 20 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 30
0.02% more ownership
Funds ownership: 0.79% → 0.82% (+0.02%)
0% more funds holding
Funds holding: 115 → 115 (0)
0% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 20
23% less capital invested
Capital invested by funds: $232M → $179M (-$53.7M)
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $486K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$10.4M |
| 2 |
BlackRock
New York
|
+$5.26M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$4.74M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.95M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$2.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$14.3M |
| 2 |
Morgan Stanley
New York
|
-$5.2M |
| 3 |
Millennium Management
New York
|
-$4.42M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$3.56M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$2.96M |
PVLA Hedge Fund Activity: Q2 2018 in Review
115 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2018, worth a combined $179M — down 23% from $232M a quarter earlier.
Fund positioning in PVLA was balanced in Q2 2018: 20 funds opened new positions, 20 closed out, 45 added to existing stakes and 30 trimmed.
The largest buyer was BVF Inc, adding an estimated $10.4M. The largest seller was OrbiMed, cutting an estimated $14.3M.
- 115 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $179M of Palvella Therapeutics stock for Q2 2018, down 23% quarter-over-quarter.
- 20 funds opened new Palvella Therapeutics positions in Q2 2018 and 20 closed out, a net change of 0 holders.
- The largest Palvella Therapeutics buyer in Q2 2018 was BVF Inc, an estimated $10.4M added.
- The largest Palvella Therapeutics seller in Q2 2018 was OrbiMed, an estimated $14.3M sold.
Based on aggregated 13F filings for Q2 2018.